iSERA Lifesciences Reports ₹13.11 Lakh Q2 FY27 Loss

iSERA Lifesciences Limited reported a net loss of ₹13.11 lakh for the quarter ended September 30, 2026, compared with a ₹0.70 lakh profit in the corresponding quarter a year earlier. The company’s loss for the first half of FY27 widened to ₹46.73 lakh, despite half-year revenue rising to ₹7.88 lakh from ₹1.00 lakh.

What did iSERA Lifesciences report for the September 2026 quarter?

iSERA Lifesciences reported a ₹13.11 lakh net loss for the quarter ended September 30, 2026. The result represents a reversal from the ₹0.70 lakh profit reported in the corresponding quarter of the previous year.

The disclosed information also compares the September-quarter loss with a ₹33.62 lakh loss in the preceding June 2026 quarter. The figures show that the company remained loss-making during the first half, even as it reported higher revenue for the six-month period.

The results relate to the quarter and half-year ended September 30, 2026, which falls in the second quarter of FY27. Some source material refers to the announcement as Q3 FY2026, but the reported period and board agenda clearly identify the September 2026 quarter and half-year.

How did iSERA Lifesciences perform in the first half of FY27?

iSERA Lifesciences posted a net loss of ₹46.73 lakh for the half-year ended September 30, 2026, against a loss of ₹0.84 lakh in the corresponding first half of FY26. Revenue for the six-month period stood at ₹7.88 lakh, compared with ₹1.00 lakh a year earlier.

The contrast between revenue growth and a larger loss is the key feature of the half-year numbers. The available disclosures do not provide a detailed expense break-up that explains every movement in profitability, so the reported figures do not establish which individual cost categories drove the wider loss.

What did the board approve on November 4, 2026?

iSERA Lifesciences’ board approved the unaudited standalone financial results for the quarter and half-year ended September 30, 2026, at its meeting held on November 4, 2026. The meeting concluded at 5:30 pm, according to the information provided.

The board also approved the independent auditor’s limited review report issued by GMKS & Co, Chartered Accountants. The company stated that the disclosed unaudited standalone results contained no material misstatement.

The meeting had been scheduled through an October 31, 2026 notice. Its primary agenda was to consider, approve and take on record the unaudited financial results for the September 2026 quarter and half-year.

What do the cash flow and asset figures indicate?

iSERA Lifesciences reported that total assets were ₹802.59 lakh as of September 30, 2026, down from ₹972.24 lakh as of June 30, 2026. This movement is relevant because the asset base declined alongside a loss-making half-year.

The company’s cash-flow commentary said operating activities generated cash, but investing and financing outflows reduced liquid reserves. It specifically identified a ₹158.30 lakh repayment of loans among the financing outflows.

The disclosures do not provide a full reconciliation of the asset decline or a detailed balance-sheet composition in the supplied material. However, the reported loan repayment and reduction in assets make liquidity and funding movements relevant areas for investors assessing the company’s financial position.

How does the result affect investors and operations?

iSERA Lifesciences’ results show that higher half-year revenue did not translate into improved profitability. For investors, the reported loss, lower asset base and financing outflows are the main disclosed financial indicators from the September 2026 results.

The company operates in the IT/ITES business in India. In this context, the results provide a current view of its standalone financial performance, but the supplied material does not include management guidance, client additions, order-book data or a forecast for future revenue and earnings.

The company also submitted a compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter and half-year ended September 30, 2026. The filing confirmed that there were no physical share certificates requiring action under the process described in the disclosure.

Conclusion

iSERA Lifesciences reported a ₹13.11 lakh loss for the September 2026 quarter and a ₹46.73 lakh loss for the first half of FY27, compared with a much smaller half-year loss a year earlier. Half-year revenue rose to ₹7.88 lakh, but the available results show that the increase was insufficient to prevent wider losses.

Investors will next watch subsequent financial disclosures for changes in revenue, costs, liquidity and the company’s asset position. The September results also highlight the significance of cash movements, particularly the disclosed ₹158.30 lakh loan repayment, because the company reported a decline in total assets to ₹802.59 lakh.